STAT+: GSK to withdraw blood cancer drug from U.S. market following confirmatory study setback

British pharma giant GSK said Tuesday that it will withdraw its blood cancer drug Blenrep from the U.S. market, following a request from the Food and Drug Administration.

Blenrep’s removal is another sign that U.S. regulators are taking a more aggressive stance toward cancer drugs approved based on preliminary evidence of efficacy.

Continue to STAT+ to read the full story…